论文部分内容阅读
目前肿瘤血管靶向治疗新药的研究主要集中在两个方向,即肿瘤血管生成抑制剂(tumor angiogenesis inhibitor,TAI)和肿瘤血管靶向制剂(vascular targeting agent,VTA)。TAI类旨在抑制肿瘤血管生成的过程,近年来研究较多的为血管内皮生长因子(VEGF)类、基质金属蛋白酶(MMP)类、血管抑素类、内皮抑素类等;而VAT类则是通过破坏肿瘤组织中已存在的血管从而使肿瘤坏死,主要包括小分子类VTA和生物类VTA。对近年来各类抗肿瘤血管治疗新药的种类、作用机制及各自的临床研究进展进行综述。
At present, the research of tumor vascular targeting treatment of new drugs mainly focuses on two directions, namely tumor angiogenesis inhibitor (TAI) and vascular targeting agent (VTA). TAI class aims to inhibit the process of tumor angiogenesis in recent years, more research for the vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), angiostatin, endostatin, etc .; and VAT The tumor is necrotic by destroying already existing blood vessels in the tumor tissue, mainly including small molecule VTA and biological VTA. In recent years, the types of anti-tumor vascular treatment of new drugs, the mechanism of action and their clinical research are reviewed.